Recent 8-K filings for ANIX
Highest-materiality recent filing
Anixa reports extended survival in ovarian cancer CAR-T trial; regulatory approval for 100x dose escalation
- 12 patients treated; 7 lived beyond expected median survival of 3-4 months; one survived 28 months.
- No dose-limiting toxicities; protocol amended to escalate from 1x10^7 to up to 1x10^9 cells/kg (100x increase).
-
Anixa holds annual meeting; re-elects four directors, approves say-on-pay and auditor ratification
Re-elected Kumar, Baskies, Gottschalk, Titterton as directors; each received 7.2M+ votes for.
-
12 patients treated; 7 lived beyond expected median survival of 3-4 months; one survived 28 months.
-
Vaccine met all primary endpoints; 74% of participants showed protocol-defined aLA-specific T cell responses.
-
Anixa Biosciences annual meeting re-elects four directors, approves say-on-pay 66%-33%
Dr. Amit Kumar, Dr. Arnold Baskies, Emily Gottschalk, Lewis Titterton re-elected as directors with 97-99% of votes cast.
-
Phase 1 trial of alpha-lactalbumin vaccine updated at SITC; data continue positive trend across 3 cohorts.
-
Anixa expands Cleveland Clinic joint development to develop additional cancer vaccines
Anixa and Cleveland Clinic entered Joint Development and Option Agreement to develop vaccines for multiple cancers.
-
Anixa Biosciences re-elects four directors and ratifies auditor at 2024 annual meeting
Dr. Amit Kumar, Dr. Arnold Baskies, Emily Gottschalk, and Lewis H. Titterton, Jr. re-elected as directors with 7.9M-7.7M votes for.
Materiality & sentiment trend
Max materiality 0.80 · Median 0.60 · Most common event other_material